0.6484

2.86% -0.0191

After Hours: .65 0.0016 +0.25%

Citius Pharmaceuticals Inc (CTXR)

Overview News Price History Option Chain Financials Why CTXR Down? Discussions Forecast Stock Split

Citius Pharmaceuticals Inc stock is currently priced at $0.6484, with a 24-hour trading volume of 891.29K. It has seen a -2.86% decreased in the last 24 hours and a -20.56% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $0.6525 pivot point. If it approaches the $0.635 support level, significant changes may occur.

Previous Close:

$0.6675

Open:

$0.67

24h Volume:

891.29K

Market Cap:

$117.15M

Revenue:

Net Income/Loss:

$-32.54M

P/E Ratio:

-3.242

EPS:

-0.2

Net Cash Flow:

$-29.06M

1W Performance:

-6.66%

1M Performance:

-20.56%

6M Performance:

-16.11%

1Y Performance:

-41.05%

1D Range:

$0.6406

$0.6728

52W Range:

$0.60

$1.40

Citius Pharmaceuticals Inc Stock (CTXR) Company Profile

Name

Citius Pharmaceuticals Inc

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

908-967-6677

Address

11 Commerce Drive, First Floor, Cranford, NJ

Employee

Twitter

Next Earnings Date

2024-05-20

Latest SEC Filings

CTXR's Discussions on Twitter

Citius Pharmaceuticals Inc Stock (CTXR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-30-21	Initiated	Maxim Group	Buy

Citius Pharmaceuticals Inc Stock (CTXR) Latest News

Analyzing the Impact of Earnings Reports on Citius Pharmaceuticals Inc Inc. (CTXR) Price Performance - The InvestChronicle

The InvestChronicle

Take off with Citius Pharmaceuticals Inc (CTXR): Get ready for trading – Sete News - SETE News

SETE News

Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business Update - PR Newswire

PR Newswire

How should investors view Citius Pharmaceuticals Inc (CTXR)? – US Post News - US Post News

US Post News

Citius (CTXR) Posts Top-Line Data From Pivotal Lymphoma Study - Yahoo News UK

Yahoo News UK

Citius Pharmaceuticals to Participate in Upcoming EF Hutton and H.C. Wainwright Investor Conferences - PR Newswire

PR Newswire

Citius Pharmaceuticals Inc Stock (CTXR) Financials Data

Citius Pharmaceuticals Inc (CTXR) Net Income 2024

CTXR net income (TTM) was -$32.54 million for the quarter ending September 30, 2023, a +3.26% increase year-over-year.

Citius Pharmaceuticals Inc (CTXR) Cash Flow 2024

CTXR recorded a free cash flow (TTM) of -$29.06 million for the quarter ending September 30, 2023, a -2.46% decrease year-over-year.

Citius Pharmaceuticals Inc (CTXR) Earnings per Share 2024

CTXR earnings per share (TTM) was -$0.22 for the quarter ending September 30, 2023, a 0.00% decline year-over-year.

Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, and prescription products. The company develops Mino-Lok product, which has completed Phase IIb clinical trials for the treatment and salvage of infected central venous catheters in patients with catheter related bloodstream infections; and Hydro-Lido product, a topical formulation of hydrocortisone and lidocaine that is intended for the treatment of hemorrhoids. It has a collaboration and license agreement with Alpex Pharma S.A. to develop and commercialize orally disintegrating tablet formulations of pharmaceutical products in United States, Canada, and Mexico. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.